{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:03:03Z","timestamp":1792544583887,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaad.2025.10.149","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T02:42:49Z","timestamp":1763606569000},"page":"879-887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of ruxolitinib cream in patients with mild to moderate hidradenitis suppurativa: Results from a randomized, double-blind, vehicle-controlled phase 2 study"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-4385","authenticated-orcid":false,"given":"Martina L.","family":"Porter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Celeste","family":"Ferreira-Cornwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haq","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2025.10.149_bib1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2133.2010.10034.x","article-title":"Hidradenitis suppurativa\/acne inversa: bilocated epithelial hyperplasia with very different sequelae","volume":"164","author":"von Laffert","year":"2011","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.10.149_bib2","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/exd.14451","article-title":"Hidradenitis suppurativa: a folliculotropic disease of innate immune barrier dysfunction?","volume":"30","author":"Johnston","year":"2021","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.149_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1600-0625.2009.00915.x","article-title":"Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis","volume":"19","author":"von Laffert","year":"2010","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.149_bib4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients' unmet needs in hidradenitis suppurativa: results from the Global Survey of Impact and Healthcare Needs (VOICE) project","volume":"82","author":"Garg","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2025.10.149_bib5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/jdv.18163","article-title":"Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US","volume":"36","author":"Ingram","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.149_bib6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40257-017-0280-2","article-title":"Assessing pruritus in hidradenitis suppurativa: a cross-sectional study","volume":"18","author":"Vossen","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.149_bib7","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/jdv.16132","article-title":"Baseline patient-reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice","volume":"34","author":"Kimball","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.149_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jaad.2020.03.041","article-title":"The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: systematic review and meta-analysis","volume":"83","author":"Jalenques","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"10.1016\/j.jaad.2025.10.149_bib9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.21037\/atm-20-1028","article-title":"Hidradenitis suppurativa and psychiatric comorbidities, suicides and substance abuse: systematic review and meta-analysis","volume":"8","author":"Phan","year":"2020","journal-title":"Ann Transl Med"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.149_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaad.2019.11.068","article-title":"Association between hidradenitis suppurativa, depression, anxiety, and suicidality: a systematic review and meta-analysis","volume":"83","author":"Patel","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"10.1016\/j.jaad.2025.10.149_bib11","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.3390\/ijerph18136709","article-title":"The burden of hidradenitis suppurativa signs and symptoms in quality of life: systematic review and meta-analysis","volume":"18","author":"Montero-Vilchez","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.149_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D330363875","article-title":"Sensitive detection of quality of life impact with a hidradenitis suppurativa specific measure","volume":"30","author":"Kelly","year":"2024","journal-title":"Dermatol Online J"},{"issue":"9","key":"10.1016\/j.jaad.2025.10.149_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D3269050156","article-title":"Physical symptoms and psychosocial problems associated with hidradenitis suppurativa: correlation with Hurley stage","volume":"26","author":"McKenzie","year":"2020","journal-title":"Dermatol Online J"},{"issue":"20","key":"10.1016\/j.jaad.2025.10.149_bib14","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.149_bib15","first-page":"868","article-title":"S2k guideline for the treatment of hidradenitis suppurativa\/acne inversa \u2013 short version","volume":"22","author":"Zouboulis","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.149_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2025.10.149_bib17","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1097\/MS9.0000000000002345","article-title":"Essentials of hidradenitis suppurativa: a comprehensive review of diagnostic and treatment perspectives","volume":"86","author":"Pandey","year":"2024","journal-title":"Ann Med Surg"},{"issue":"8","key":"10.1016\/j.jaad.2025.10.149_bib18","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s13555-023-00956-6","article-title":"Emerging treatments and the clinical trial landscape for hidradenitis suppurativa part I: topical and systemic medical therapies","volume":"13","author":"Fragoso","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2025.10.149_bib19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000542343","article-title":"Treatment satisfaction in patients with hidradenitis suppurativa: a real-world survey from the EU5 and US","volume":"241","author":"Ingram","year":"2025","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.149_bib20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/bjd.21798","article-title":"Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the global VOICE project","volume":"187","author":"Midgette","year":"2022","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.149_bib21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.10.149_bib22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00011-020-01381-7","article-title":"Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis","volume":"69","author":"Rumberger","year":"2020","journal-title":"Inflamm Res"},{"issue":"15","key":"10.1016\/j.jaad.2025.10.149_bib23","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jaad.2025.10.149_bib24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/pharmaceutics13071044","article-title":"Developing a JAK inhibitor for targeted local delivery: ruxolitinib cream","volume":"13","author":"Smith","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jaad.2025.10.149_bib25","series-title":"Opzelura\u00ae (ruxolitinib cream). Full Prescribing Information","year":"2025"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.149_bib26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/bjd\/ljae495","article-title":"Pilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa","volume":"192","author":"Schell","year":"2025","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.149_bib27","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jdv.15332","article-title":"Rates of antibiotic resistance\/sensitivity in bacterial cultures of hidradenitis suppurativa patients","volume":"33","author":"Bettoli","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"14","key":"10.1016\/j.jaad.2025.10.149_bib28","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.3390\/jcm13144246","article-title":"Antimicrobial resistance trends in hidradenitis suppurativa lesions","volume":"13","author":"Koumaki","year":"2024","journal-title":"J Clin Med"},{"issue":"10378","key":"10.1016\/j.jaad.2025.10.149_bib29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.149_bib30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.149_bib31","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.149_bib32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdin.2020.09.005","article-title":"Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: implications for outcome measures and trial design","volume":"1","author":"Frew","year":"2020","journal-title":"JAAD Int"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.149_bib33","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"10.1016\/j.jaad.2025.10.149_bib34","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.149_bib35","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies","volume":"88","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.149_bib36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40257-024-00855-2","article-title":"Efficacy, safety, and long-term disease control of ruxolitinib cream among adolescents with atopic dermatitis: pooled results from two randomized phase 3 studies","volume":"25","author":"Eichenfield","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.149_bib37","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","article-title":"Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies","volume":"22","author":"Gong","year":"2021","journal-title":"Am J Clin Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225032359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225032359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:16:17Z","timestamp":1773918977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225032359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0190962225032359"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.10.149","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ruxolitinib cream in patients with mild to moderate hidradenitis suppurativa: Results from a randomized, double-blind, vehicle-controlled phase 2 study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.10.149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}